{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T13:26:23Z","timestamp":1699449983464},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135054","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T18:18:24Z","timestamp":1438712304000},"page":"e0135054","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data"],"prefix":"10.1371","volume":"10","author":[{"given":"Merlijn W. J.","family":"van Leent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Stevanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Beinema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus R. B. J.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,8,4]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"MD Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"ref2","unstructured":"Lambooij MS. DHW Risico's en gebrekkige afstemming in de trombosezorg. 2010;RIVM-rapport 260242001."},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"C Kearon","year":"2008","journal-title":"Chest"},{"key":"ref4","unstructured":"Nederlands Huisartsen Genootschap. NHG-standaard diep veneuze trombose M86 2008; Available at: https:\/\/www.nhg.org\/standaarden\/samenvatting\/diepe-veneuze-tromboseAccessed2014February6<\/ext-link>."},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3111\/13696998.2013.858634","article-title":"Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism","volume":"17","author":"P Lefebvre","year":"2014","journal-title":"J Med Econ"},{"key":"ref6","unstructured":"Nederlands Huisartsen Genootschap. NHG-standaard atriumfibrilleren M79. 2013; Available at: https:\/\/www.nhg.org\/standaarden\/samenvatting\/atriumfibrillerenAccessed2014February5<\/ext-link>."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1368-5031.2006.00790.x","article-title":"Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice","volume":"60","author":"L Boulanger","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"6","key":"ref8","first-page":"1052","article-title":"Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon","volume":"100","author":"M Beinema","year":"2008","journal-title":"Thromb Haemost"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.semvascsurg.2011.11.003","article-title":"Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial","volume":"24","author":"TK Liem","year":"2011","journal-title":"Semin Vasc Surg"},{"issue":"Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"J Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharmthera.2010.12.007","article-title":"The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism","volume":"130","author":"T Mavrakanas","year":"2011","journal-title":"Pharmacol Ther"},{"key":"ref12","unstructured":"De Commissie Farmaceutische Hulp (CFH)CFH rapport Rivaroxaban (Xarelto). 2012;2012059711."},{"key":"ref13","unstructured":"Health Council of the Netherlands.New Anticoagulants: A well-dosed introduction. 2012;2012\/07."},{"key":"ref14","article-title":"Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis","author":"S Schulman","year":"2013","journal-title":"Circulation"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"ref16","unstructured":"Wet medisch-wetenschappelijk onderzoek met mensen [Dutch act on research involving human subjects]. 1998; Available at: http:\/\/wetten.overheid.nl\/BWBR0009408\/geldigheidsdatum_23-03-201503\/23<\/ext-link>."},{"key":"ref17","article-title":"Declaration of Helsinki","year":"2013","journal-title":"Ethical principles for medical research involving human subjects"},{"key":"ref18","unstructured":"Nederlandse Zorgautoriteit. Beleidsregel TB-CU-7053-02. 2013; Available at: http:\/\/www.nza.nl\/98174\/139255\/654366\/TB-CU-7053-02.pdfAccessed2014April15<\/ext-link>."},{"key":"ref19","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H. Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of data from RE-COVER and RE-COVER II. ESC Congress, Barcelona 2014 Aug 30. Available at: http:\/\/spo.escardio.org\/SessionDetails.aspx?eevtid=69&sessId=14108&subSessId=3787#.VW6rts_tmko<\/ext-link>) Accessed201506\/01."},{"key":"ref20","unstructured":"De Commissie Farmaceutische Hulp (CFH) Herbeoordeling Dabigatran (Pradaxa). 2012;2011054920 V1."},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"109","author":"R De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.thromres.2013.09.015","article-title":"Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective","volume":"132","author":"CD Seaman","year":"2013","journal-title":"Thrombosis Research"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","article-title":"The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies","volume":"15","author":"LM Lamers","year":"2006","journal-title":"Health Econ"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"JV Freeman","year":"2011","journal-title":"Ann Intern Med"},{"issue":"6","key":"ref26","first-page":"1336","article-title":"Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences","volume":"92","author":"M Locadia","year":"2004","journal-title":"Thromb Haemost"},{"key":"ref27","unstructured":"Z-Index. Apotheek Inkoop Prijzen. 2014; Available at: http:\/\/www.z-index.nl\/Accessed2014April24<\/ext-link>."},{"key":"ref28","unstructured":"Federatie van Nederlandse Trombosediensten (FNT)De waarde van trombosediensten in Nederland. 2011."},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/j.1538-7836.2009.03627.x","article-title":"Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual","volume":"7","author":"AJ Ten Cate-Hoek","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","author":"SV Shah","year":"2011","journal-title":"Circulation"},{"key":"ref31","article-title":"Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg","author":"L Hakkaart-van Roijen","year":"2010","journal-title":"Geactualiseerde versie"},{"key":"ref32","unstructured":"Global- rates. Inflatie Nederland. 2014; Available at: http:\/\/nl.global-rates.com\/economische-statistieken\/inflatie\/consumentenprijzen\/cpi\/nederland.aspxAccessed2014April14<\/ext-link>."},{"key":"ref33","unstructured":"Council for Public Helath and Health CareSensible and Sustainable Care. Zoetermeer (2006)."},{"key":"ref34","author":"AH Briggs","year":"2006"},{"key":"ref35","article-title":"Personalised treatment with oral anticoagulant drugs clinical and economic issues","author":"TI Verhoef","year":"2013"},{"key":"ref36","article-title":"Intensieve begeleiding bij DOAC's en VKA's cruciaal","volume":"07","author":"K Brouwers","year":"2014","journal-title":"Pharmaceutisch Weekblad"},{"key":"ref37","article-title":"Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin","author":"EL De Schryver","year":"2012","journal-title":"The Cochrane Library"},{"key":"ref38","article-title":"The patient perspective on anticoagulant therapy of deep venous thrombosis and pulmonary embolism","author":"J Brouwers","year":"2013"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"g4681","DOI":"10.1136\/bmj.g4681","article-title":"The trouble with dabigatran","volume":"349","author":"B Charlton","year":"2014","journal-title":"BMJ"},{"key":"ref40","article-title":"Vraagtekens bij de nieuwe antistollingsmiddelen","author":"PM Engelfriet","journal-title":"Alarmerend signaal over de introductie van NOAC\u2019s"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"g4517","DOI":"10.1136\/bmj.g4517","article-title":"Dabigatran, bleeding, and the regulators","volume":"349","author":"TJ Moore","year":"2014","journal-title":"BMJ"},{"key":"ref42","article-title":"Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and\/or pulmonary embolism"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:02:05Z","timestamp":1540029725000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135054"}},"subtitle":[],"editor":[{"given":"Carmine","family":"Pizzi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,4]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135054","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,4]]}}}